Yesterday, AstraZeneca signed a deal valued up to $727M for the rights to Inovio Pharmaceutical’s INO-3112 which utilizes electroporation to target the oncogenes of HPV and deliver IL-12 to HPV causing cancers like cervical and head and neck cancer. AstraZeneca will also pay all development associated costs and royalties on product sales. This is highly significant as OncoSec is a spinoff of Inovio and both are developing a pipeline around electroporation. Importantly, head and neck cancer is the only tumor type both companies are working on to treat with IL-12, and OncoSec is further along having already started enrollment of its Phase 2 trial. This deal is huge for OncoSec because it not only validates the electroporation technology but also, as I’ve written about before, highlights the increasing interest by big pharma to leverage various immuno-oncology platforms. Make no mistake, OncoSec will partner ImmunoPulse IL-12 but the longer it accumulates data and illustrates efficacy the more beneficial the deal will be. I'm going to post another part of a document I think you all will find most informative if you read between the lines..I stumbled on it by chance.It helps to put 2 and 2 together.
of many.Most companys in this field have one or two projects in the works and carry a higher retail stock price..I suggest you buy while you can..A word to the wise is sufficient..
Sentiment: Strong Buy
good for you,I did the other day...An better days are coming..
I just posted..
Sentiment: Strong Buy
Pucker up time if your rite and I think ur Joe.
it would take nearly THREE WEEKS to repurchase all of these shares, at the equity's average daily volume.they should put this to music..!
•INO is moving higher on a deal of its own this morning, jumping 24.4% to $8.08. The drugmaker sold the rights to an experimental cancer immunotherapy to AstraZeneca plc (ADR) (NYSE:AZN) in a deal worth $27.5 million upfront, and up to $700 million more in future milestone payments. This is a boost the shares desperately need, as Inovio Pharmaceuticals Inc has trailed the S&P 500 Index (SPX) by more than 14 percentage points in the past two months. This disappointing price action has brought short sellers to the stock's door. Over 21% of INO's float has been sold short, and it would take nearly three weeks to repurchase all of these shares, at the equity's average daily volume.
announced that it has entered into a license agreement and collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.
Under the agreement, MedImmune will acquire exclusive rights to Inovio’s INO-3112 immunotherapy, which targets cancers caused by human papillomavirus (HPV) types 16 and 18. INO-3112, which is in phase I/II clinical trials for cervical and head and neck cancers, works by generating killer T-cell responses that are able to destroy HPV 16- and 18-driven tumors. These HPV types are responsible for more than 70 percent of cervical pre-cancers and cancers.
MedImmune intends to study INO-3112 in combination with selected immunotherapy molecules within its pipeline in HPV-driven cancers. Emerging evidence suggests that the benefits from immuno-oncology molecules, such as those in MedImmune’s portfolio, can be enhanced when they are used in combination with cancer vaccines that generate tumor-specific T-cells.
Under the terms of the agreement, MedImmune will make an upfront payment of $27.5 million to Inovio as well as potential future payments upon reaching development and commercial milestones totaling up to $700 million. MedImmune will fund all development costs. Inovio is entitled to receive up to double-digit tiered royalties on INO-3112 product sales.
Within the broader collaboration, MedImmune and Inovio will develop up to two additional DNA-based cancer vaccine products not included in Inovio’s current product pipeline, which MedImmune will have the exclusive rights to develop and commercialize. Inovio will receive development, regulatory and commercialization milestone payments and will be eligible to receive royalties on worldwide net sales for these additional cancer vaccine products.
Dr. David Berman, Senior Vice President and Head of the Oncology Innovative Medicines unit, MedImmune, said: “Today’s collaboration with Inovio leverages our deep internal expertise in the use of vaccines to drive antigen-spe
The R/S was the beginning ,trust is a double edge sword ,so far nothing at all behind anything he has said. Maybe he made a mistake when he bought also.He drank his own kool-aid.
Seems the low hanging fruit shriveled up on the vine..At one time you couldn't shut them up. But how many down days can you absorb as they get progressively worse? I'm still in thou..I don't know why.